{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:51:57Z","timestamp":1790423517422,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T00:00:00Z","timestamp":1438128000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s40265-015-0444-4","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T10:50:51Z","timestamp":1438080651000},"page":"1435-1445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Aflibercept: A Review in Metastatic Colorectal Cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Yahiya Y.","family":"Syed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"McKeage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,29]]},"reference":[{"issue":"12","key":"444_CR1","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893\u2013917.","journal-title":"Int J Cancer"},{"key":"444_CR2","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii1\u20139.","DOI":"10.1093\/annonc\/mdu260"},{"key":"444_CR3","unstructured":"American Cancer Society. What are the survival rates for colorectal cancer by stage? 2013. http:\/\/www.cancer.org . Accessed 12 May 2015."},{"issue":"2","key":"444_CR4","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/j.1463-1318.2011.02765.x","volume":"14","author":"MS Edwards","year":"2012","unstructured":"Edwards MS, Chadda SD, Zhao Z, et al. A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis. 2012;14(2):e31\u201347.","journal-title":"Colorectal Dis"},{"key":"444_CR5","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): colon cancer, version 2.2015. 2014. http:\/\/www.nccn.org . Accessed 12 May 2015."},{"key":"444_CR6","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): rectal cancer, version 2.2015. 2014. http:\/\/www.nccn.org . Accessed 12 May 2015."},{"key":"444_CR7","first-page":"59","volume":"5","author":"K He","year":"2012","unstructured":"He K, Cui B, Li G, et al. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther. 2012;5:59\u201365.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"444_CR8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1756283X13502637","volume":"6","author":"PA Tang","year":"2013","unstructured":"Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol. 2013;6(6):459\u201373.","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"444_CR9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2165\/00003495-200868040-00009","volume":"68","author":"PL McCormack","year":"2008","unstructured":"McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68(4):487\u2013506.","journal-title":"Drugs."},{"issue":"2","key":"444_CR10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis"},{"issue":"12","key":"444_CR11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/nrc2524","volume":"8","author":"C Fischer","year":"2008","unstructured":"Fischer C, Mazzone M, Jonckx B, et al. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer. 2008;8(12):942\u201356.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"444_CR12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ctrv.2011.12.008","volume":"38","author":"A Gaya","year":"2012","unstructured":"Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38(5):484\u201393.","journal-title":"Cancer Treat Rev"},{"issue":"17","key":"444_CR13","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393\u20138.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"444_CR14","unstructured":"sanofi-aventis. Zaltrap\u00ae (aflibercept): US Prescribing information. 2012. http:\/\/www.fda.gov . Accessed 12 May 2015."},{"key":"444_CR15","unstructured":"European Medicines Agency. Zaltrap (aflibercept): EU summary of product characteristics. 2013. http:\/\/www.ema.europa.eu . Accessed 12 May 2015."},{"key":"444_CR16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0959-8049(14)70532-5","volume":"50","author":"A Bouygues","year":"2014","unstructured":"Bouygues A, Mesange P, Ayadi M, et al. Aflibercept (Zaltrap) directly attenuates the migration and invasion of colorectal cancer cells. Eur J Cancer. 2014;50:130.","journal-title":"Eur J Cancer"},{"issue":"2","key":"444_CR17","doi-asserted-by":"crossref","first-page":"H547","DOI":"10.1152\/ajpheart.00616.2005","volume":"290","author":"F Baffert","year":"2006","unstructured":"Baffert F, Le T, Sennino B, et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol. 2006;290(2):H547\u201359.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"444_CR18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10456-012-9328-3","volume":"16","author":"A Eichten","year":"2013","unstructured":"Eichten A, Adler AP, Cooper B, et al. Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models. Angiogenesis. 2013;16(2):429\u201341.","journal-title":"Angiogenesis"},{"issue":"12","key":"444_CR19","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.4161\/cbt.10.12.14009","volume":"10","author":"W Lassoued","year":"2010","unstructured":"Lassoued W, Murphy D, Tsai J, et al. Effect of VEGF and VEGF Trap on vascular endothelial cell signaling in tumors. Cancer Biol Ther. 2010;10(12):1326\u201333.","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"444_CR20","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/1535-7163.MCT-13-0753","volume":"13","author":"M Chiron","year":"2014","unstructured":"Chiron M, Bagley RG, Pollard J, et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther. 2014;13(6):1636\u201344.","journal-title":"Mol Cancer Ther"},{"key":"444_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0959-8049(14)70417-4","volume":"50","author":"C Dib","year":"2014","unstructured":"Dib C, Bagley RG, Mankoo P, et al. Aflibercept has anti-tumor activity in bevacizumab-escaping tumors of colorectal cancer: Molecular profiles and mechanisms. Eur J Cancer. 2014;50:96.","journal-title":"Eur J Cancer"},{"issue":"4","key":"444_CR22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ejca.2012.10.012","volume":"49","author":"D Khayat","year":"2013","unstructured":"Khayat D, Tejpar S, Spano J-P, et al. Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study. Eur J Cancer. 2013;49(4):790\u20137.","journal-title":"Eur J Cancer"},{"issue":"2","key":"444_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1200\/JCO.2009.22.9237","volume":"28","author":"AC Lockhart","year":"2010","unstructured":"Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010;28(2):207\u201314.","journal-title":"J Clin Oncol"},{"issue":"4","key":"444_CR24","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1007\/s10637-012-9895-6","volume":"31","author":"T Yoshino","year":"2013","unstructured":"Yoshino T, Yamazaki K, Yamaguchi K, et al. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Invest New Drugs. 2013;31(4):910\u20137.","journal-title":"Invest New Drugs"},{"issue":"1","key":"444_CR25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2012.07.007","volume":"49","author":"E Cutsem Van","year":"2013","unstructured":"Van Cutsem E, Khayat D, Verslype C, et al. Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours. Eur J Cancer. 2013;49(1):17\u201324.","journal-title":"Eur J Cancer"},{"issue":"28","key":"444_CR26","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Cutsem Van","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499\u2013506.","journal-title":"J Clin Oncol"},{"key":"444_CR27","doi-asserted-by":"crossref","unstructured":"Sims TN, Gao B, Phillips R, et al. Potential predictive and prognostic biomarkers identified in baseline plasma samples from the VELOUR trial [abstract no. 638]. J Clin Oncol. 2015;33(Suppl 3).","DOI":"10.1200\/jco.2015.33.3_suppl.638"},{"issue":"21","key":"444_CR28","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1158\/1078-0432.CCR-11-3252","volume":"18","author":"PA Tang","year":"2012","unstructured":"Tang PA, Cohen SJ, Kollmannsberger C, et al. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res. 2012;18(21):6023\u201331.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"444_CR29","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00280-013-2182-1","volume":"72","author":"HT Thai","year":"2013","unstructured":"Thai HT, Veyrat-Follet C, Mentre F, et al. Population pharmacokinetic analysis of free and bound aflibercept in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;72(1):167\u201380.","journal-title":"Cancer Chemother Pharmacol"},{"key":"444_CR30","doi-asserted-by":"crossref","unstructured":"Ferry D, Kim TW, Guren TK, et al. On-treatment progression-free survival analysis of ziv-aflibercept\/FOLFIRI treatment within 28\u00a0days of end of treatment in metastatic colorectal cancer: updated efficacy results from the VELOUR study [abstract no. 3573]. J Clin Oncol. 2013;31(Suppl 15).","DOI":"10.1200\/jco.2013.31.4_suppl.469"},{"issue":"7","key":"444_CR31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/bjc.2013.523","volume":"109","author":"F Joulain","year":"2013","unstructured":"Joulain F, Proskorovsky I, Allegra C, et al. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. Br J Cancer. 2013;109(7):1735\u201343.","journal-title":"Br J Cancer"},{"issue":"2","key":"444_CR32","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","volume":"50","author":"J Tabernero","year":"2013","unstructured":"Tabernero J, Van Cutsem E, Lakomy R, et al. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2013;50(2):320\u201331.","journal-title":"Eur J Cancer"},{"issue":"1","key":"444_CR33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1186\/1471-2407-14-605","volume":"14","author":"I Chau","year":"2014","unstructured":"Chau I, Joulain F, Iqbal SU, et al. A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI. BMC Cancer. 2014;14(1):605.","journal-title":"BMC Cancer"},{"issue":"1","key":"444_CR34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2014.10.019","volume":"51","author":"P Ruff","year":"2015","unstructured":"Ruff P, Ferry DR, Lakomy R, et al. Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. Eur J Cancer. 2015;51(1):18\u201326.","journal-title":"Eur J Cancer"},{"key":"444_CR35","doi-asserted-by":"crossref","unstructured":"Taieb J, Bordonaro R, Siena S, et al. Quality of life maintained on the ziv-aflibercept\/FOLFIRI regimen: third interim analysis of the global aflibercept safety and HR-QOL program [abstract no. e14560]. J Clin Oncol. 2014;32(Suppl 15).","DOI":"10.1200\/jco.2014.32.15_suppl.e14560"},{"key":"444_CR36","doi-asserted-by":"crossref","unstructured":"Frassineti L, Di Bartolomeo M, Heinemann V, et al. Aflibercept\u00a0+\u00a0FOLFIRI for treatment of metastatic colorectal cancer after oxaliplatin failure: 4th interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQOP\/AFEQT studies) [abstract no. 528P]. Ann Oncol. 2014;25(Suppl 4):iv167\u2013iv209.","DOI":"10.1093\/annonc\/mdu333.31"},{"key":"444_CR37","doi-asserted-by":"crossref","unstructured":"Sobrero AF, Bordonaro R, Bencardino K, et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B). [abstract no. 528]. J Clin Oncol. 2015;33(Suppl 3).","DOI":"10.1200\/jco.2015.33.3_suppl.528"},{"key":"444_CR38","doi-asserted-by":"crossref","unstructured":"Abdelghani MB, Borg C, Dourthe LM, et al. Aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: first interim safety data from AFEQT trial [abstract no. 661]. J Clin Oncol. 2015;33(Suppl 3).","DOI":"10.1200\/jco.2015.33.3_suppl.661"},{"key":"444_CR39","doi-asserted-by":"crossref","unstructured":"Bordonaro R, Frassineti GL, Ciuffreda L, et al. Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients \u226565 [abstract no. 545]. J Clin Oncol. 2014;33(Suppl 3).","DOI":"10.1200\/jco.2015.33.3_suppl.588"},{"issue":"12","key":"444_CR40","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s12094-013-1082-5","volume":"15","author":"E Casado-Saenz","year":"2013","unstructured":"Casado-Saenz E, Feliu J, Gomez-Espana MA, et al. SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013. Clin Transl Oncol. 2013;15(12):996\u20131003.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"444_CR41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013;14(1):29\u201337.","journal-title":"Lancet Oncol."},{"key":"444_CR42","unstructured":"National Institute for Health and Care Excellence. Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy. 2014. http:\/\/www.nice.org.uk . Accessed 12 May 2015."},{"key":"444_CR43","doi-asserted-by":"crossref","unstructured":"Huff K, Drea E, Hennessy D, et al. Budgetary impact of adding ziv-aflibercept to a United States health plan formulary as a post-oxaliplatin biologic option for patients with metastatic colorectal cancer (mCRC) [abstract no. 765]. J Clin Oncol. 2015;33(Suppl 3).","DOI":"10.1200\/jco.2015.33.3_suppl.765"},{"issue":"7","key":"444_CR44","doi-asserted-by":"crossref","first-page":"A621","DOI":"10.1016\/j.jval.2014.08.2199","volume":"17","author":"MP Kaczor","year":"2014","unstructured":"Kaczor MP, Pawlik D, Wojcik R, et al. Budget impact analysis of aflibercept in the treatment of metastatic colorectal cancer (MCRC) in Poland [abstract no. PCN41]. Value Health. 2014;17(7):A621.","journal-title":"Value Health"},{"key":"444_CR45","doi-asserted-by":"crossref","unstructured":"Chen CX, Sadeghi S, Lenz HJ, et al. Comparative effectiveness of antiangiogenesis inhibitors for second-line therapy of metastatic colorectal cancer [abstract no. 9]. J Clin Oncol. 2014;32(Suppl 30).","DOI":"10.1200\/jco.2014.32.30_suppl.9"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0444-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-015-0444-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-015-0444-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T20:23:20Z","timestamp":1567023800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-015-0444-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,29]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1007\/s40265-015-0444-4","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,29]]}}}